公开(公告)号：US20240327390A1

公开(公告)日：2024-10-03

申请号：US18659052

申请日：2024-05-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

CPC classification number: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I)




or a salt thereof,

wherein R1 is:





each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20190248769A1

公开(公告)日：2019-08-15

申请号：US16344823

申请日：2017-11-02

Applicant: Bristol-Myers Squibb Company

Inventor： Prashantha Gunaga ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Manoranjan Panda ,  Navnath Dnyanoba Yadav ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P9/12 ,  A61P9/04 ,  A61P13/02 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20180346453A1

公开(公告)日：2018-12-06

申请号：US15993683

申请日：2018-05-31

Applicant: Bristol-Myers Squibb Company

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D417/14 ,  C07D413/14

CPC classification number: C07D413/14 ,  C07D405/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20220144818A1

公开(公告)日：2022-05-12

申请号：US17601942

申请日：2020-04-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  Jianxin Feng ,  Pratik Devasthale ,  Natesan Murugesan ,  Bruce A. Ellsworth ,  Alicia Regueiro-Ren ,  Susheel Jethanand Nara ,  Prasada Rao Jalagam ,  Manoranjan Panda

IPC: C07D417/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14

Abstract: The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US11267811B2

公开(公告)日：2022-03-08

申请号：US16650403

申请日：2018-09-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prasada Rao Jalagam ,  Satheesh Kesavan Nair ,  Manoranjan Panda ,  Ramakanth Sarabu ,  Jacob Swidorski ,  Brett R. Beno ,  Alicia Regueiro-Ren

IPC: C07D417/14 ,  C07D405/14

Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US10851108B2

公开(公告)日：2020-12-01

申请号：US16094288

申请日：2017-04-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prashantha Gunaga ,  Jeremy Richter ,  Navnath Dnyanoba Yadav ,  Manoranjan Panda ,  Sreenivasulu Godesi

IPC: A61K31/519 ,  C07D487/04 ,  C07D471/04 ,  C07D271/04 ,  C07D407/04 ,  C07D407/06 ,  C07D413/14 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R1 is Formulae (A) or (B); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, R3, R4, L1, R1a, R1b, R1c, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20200308213A1

公开(公告)日：2020-10-01

申请号：US16754381

申请日：2018-10-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Prasada Rao Jalagam ,  Satheesh Kesavan Nair ,  Manoranjan Panda ,  Alicia Regueiro-Ren

IPC: C07H19/056 ,  C07H19/24 ,  C07H19/052

Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US11639353B2

公开(公告)日：2023-05-02

申请号：US17212210

申请日：2021-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61K31/4375 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20230124468A1

公开(公告)日：2023-04-20

申请号：US17960199

申请日：2022-10-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Navnath Dnyanoba Yadav ,  Rajeev S. Bhide ,  Rajesh Onkardas Bora ,  Prashantha Gunaga ,  Manoranjan Panda ,  Eldon Scott Priestley ,  Jeremy Richter

IPC: C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

公开(公告)号：US20210246136A1

公开(公告)日：2021-08-12

申请号：US17212210

申请日：2021-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.